{"organizations": [], "uuid": "e766eeb7e05f18f6512db3ffc239019a2b5bc58a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180228.html", "section_title": "Archive News &amp; Video for Wednesday, 28 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-china-biologic-reports-q4-adjusted/brief-china-biologic-reports-q4-adjusted-non-gaap-earnings-per-share-0-90-idUSASB0C85L", "country": "US", "domain_rank": 408, "title": "BRIEF-China Biologic Reports Q4 Adjusted Non-GAAP Earnings Per Share $0.90", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.831, "site_type": "news", "published": "2018-03-01T06:06:00.000+02:00", "replies_count": 0, "uuid": "e766eeb7e05f18f6512db3ffc239019a2b5bc58a"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-china-biologic-reports-q4-adjusted/brief-china-biologic-reports-q4-adjusted-non-gaap-earnings-per-share-0-90-idUSASB0C85L", "ord_in_thread": 0, "title": "BRIEF-China Biologic Reports Q4 Adjusted Non-GAAP Earnings Per Share $0.90", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "china biologic products holdings inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 28 (Reuters) - China Biologic Products Holdings Inc :\n* CHINA BIOLOGIC REPORTS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FISCAL YEAR 2017\n* Q4 ADJUSTED NON-GAAP EARNINGS PER SHARE $0.90\n* Q4 LOSS PER SHARE $0.86 * ‍TOTAL SALES IN Q4 OF 2017 INCREASED BY 12.2% IN RMB TERMS AND 16.1% IN USD TERMS TO $90.1 MILLION\n* ‍FOR FULL YEAR OF 2018, COMPANY EXPECTS TOTAL SALES TO GROW 18% TO 20% IN RMB TERMS​\n* ‍FOR FULL YEAR OF 2018, EXPECTS NON-GAAP ADJUSTED NET INCOME TO GROW 16% TO 18% IN RMB TERMS\n* ‍EXCLUDING TIANXINFU CONTRIBUTION, ESTIMATED SALES FOR 2018 ARE EXPECTED TO GROW 6% TO 8% IN RMB TERMS​\n* CHINA BIOLOGIC PRODUCTS HOLDINGS - ‍ EXCLUDING TIANXINFU CONTRIBUTION, FY 2018 NON-GAAP ADJUSTED NET INCOME IS EXPECTED TO GROW 3% TO 4% IN RMB TERMS​ Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-01T06:06:00.000+02:00", "crawled": "2018-03-01T21:18:06.062+02:00", "highlightTitle": ""}